Iterum rises after FDA agrees on design for UTI drug trial

Iterum Therapeutics

11/07/2022 16:50

** U.S.-listed shares of Dublin-based drug developer
 ITRM.O  rise 67.7% to $0.40
    ** Co reaches agreement with U.S. FDA under special protocol
assessment (SPA) process on design, goals and statistical
analysis of a late-stage trial for oral sulopenem, its candidate
to treat a type of urinary tract infection
    ** Study is intended to support the potential re-submission
of co's application to FDA for approval of oral sulopenem - ITRM
    ** Study to be conducted pursuant to SPA agreement, will
enroll ~1,966 patients and is anticipated to start enrolling in
Q4 
    ** Stock up 2.9% YTD

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com;))